​

Revolution Medicines (RVMD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

RVMD Stock Forecast

Revolution Medicines (RVMD) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $154.80, with a high of $200.00 and a low of $73.00. This represents a 14.41% increase from the last price of $135.30.

- $40 $80 $120 $160 $200 High: $200 Avg: $154.8 Low: $73 Last Closed Price: $135.3

RVMD Stock Rating

Revolution Medicines stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 1 Strong Buy (4.55%), 20 Buy (90.91%), 1 Hold (4.55%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 1 20 1 Strong Sell Sell Hold Buy Strong Buy

RVMD Price Target Upside V Benchmarks

TypeNameUpside
StockRevolution Medicines14.41%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts5620
Avg Price Target$174.20$169.17$128.10
Last Closing Price$135.30$135.30$135.30
Upside/Downside28.75%25.03%-5.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26416---20
Mar, 26416---20
Feb, 26416---20
Jan, 26416---20
Dec, 25417---21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 14, 2026Guggenheim$175.00$136.3028.39%29.34%
Apr 14, 2026Evercore ISI$200.00$136.3046.74%47.82%
Apr 14, 2026RBC Capital$162.00$136.3018.86%19.73%
Apr 14, 2026Robert BurnsH.C. Wainwright$169.00$136.3023.99%24.91%
Apr 13, 2026Oppenheimer$165.00$134.8822.33%21.95%
Feb 26, 2026Eva Fortea VerdejoWells Fargo$144.00$103.2439.48%6.43%
Jan 27, 2026Jay OlsonOppenheimer$150.00$97.7853.41%10.86%
Jan 22, 2026UBS$170.00$117.8544.25%25.65%
Jan 21, 2026Leonid TimashevRBC Capital$140.00$116.2220.46%3.47%
Jan 20, 2026Guggenheim$160.00$120.2833.02%18.26%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 14, 2026GuggenheimBuyBuyhold
Apr 14, 2026Evercore ISIOutperformOutperformhold
Apr 14, 2026RBC CapitalOutperformOutperformhold
Apr 14, 2026H.C. WainwrightBuyBuyhold
Apr 13, 2026OppenheimerOutperformOutperformhold
Feb 26, 2026Wells FargoOverweightOverweighthold
Feb 17, 2026BenchmarkOverweightOverweighthold
Jan 27, 2026OppenheimerOutperformOutperformhold
Jan 21, 2026RBC CapitalOutperformOutperformhold
Jan 20, 2026GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.47$-3.08$-3.86$-3.58$-5.95---
Avg Forecast$-2.50$-3.29$-3.48$-3.47$-3.93$-4.05$-3.71$-1.65
High Forecast$-2.50$-3.29$-3.29$-3.36$-3.72$-2.37$1.56$-1.65
Low Forecast$-2.50$-3.29$-3.77$-3.96$-4.58$-4.64$-6.12$-1.65
Surprise %-1.20%-6.38%10.92%3.17%51.40%---

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$29.39M$35.38M$11.58M-----
Avg Forecast$28.78M$27.86M$12.65M$300.00K$5.87M$19.77M$178.13M$589.38M
High Forecast$28.78M$27.86M$17.96M$300.00K$5.87M$19.77M$178.13M$589.38M
Low Forecast$28.78M$27.86M$11.52M$300.00K$5.87M$19.77M$178.13M$589.38M
Surprise %2.11%26.98%-8.47%-----

Net Income Forecast

$-2B $-1B $-700M $-300M $100M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-187.09M$-248.71M$-436.37M$-600.09M$-1.13B---
Avg Forecast$-168.05M$-186.58M$-436.37M$-414.33M$-469.55M$-396.42M$-608.95M$-186.78M
High Forecast$-134.44M$-149.26M$-349.09M$-380.55M$-420.48M$-267.64M$176.54M$-186.78M
Low Forecast$-201.66M$-223.89M$-523.64M$-448.11M$-518.62M$-525.20M$-692.17M$-186.78M
Surprise %11.33%33.30%-44.83%140.93%---

RVMD Forecast FAQ

Is Revolution Medicines stock a buy?

Revolution Medicines stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 20 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Revolution Medicines is a favorable investment for most analysts.

What is Revolution Medicines's price target?

Revolution Medicines's price target, set by 22 Wall Street analysts, averages $154.8 over the next 12 months. The price target range spans from $73 at the low end to $200 at the high end, suggesting a potential 14.41% change from the previous closing price of $135.3.

How does Revolution Medicines stock forecast compare to its benchmarks?

Revolution Medicines's stock forecast shows a 14.41% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Revolution Medicines over the past three months?

  • April 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Revolution Medicines’s EPS forecast?

Revolution Medicines's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.05, marking a -31.93% decrease from the reported $-5.95 in 2025. Estimates for the following years are $-3.71 in 2027, and $-1.65 in 2028.

What is Revolution Medicines’s revenue forecast?

Revolution Medicines's average annual revenue forecast for its fiscal year ending in December 2026 is $19.77M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $178.13M, and $589.38M for 2028.

What is Revolution Medicines’s net income forecast?

Revolution Medicines's net income forecast for the fiscal year ending in December 2026 stands at $-396M, representing a -64.96% decrease from the reported $-1.131B in 2025. Projections indicate $-609M in 2027, and $-187M in 2028.